Short answer
TG THERAPEUTICS, INC. (TGTX) filed an 8-K current report with the SEC on June 3, 2026 reporting Item 8.01 (Other Events). Positive Phase 1 PK, PD, safety, and tolerability data for subcutaneous ublituximab in relapsing multiple sclerosis.
TG THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Positive Phase 1 PK, PD, safety, and tolerability data for subcutaneous ublituximab in relapsing multiple sclerosis
- Potential BRIUMVI® administration convenience improvement versus existing formulation
- Early-stage findings require further clinical validation before commercial or regulatory impact
- Full study details and data context available in Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TG THERAPEUTICS, INC. 8-K filings
Get the next TGTX 8-K as it lands
Follow TGTX for push alerts, or ask the research agent what this filing means.